Astrazeneca Pharmaceuticals LP
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersSouth San Francisco, CA
US patents38
SAM.gov UEIE5K2ZJ8CTJH4
CAGE code36WK2
Incorporated inDE
Patents
38 US patents granted 2012–2020, none of them in the five years to SEP 2025.
Pharmaceuticals 31Medical technology 3Measurement 2IT methods for management 1Organic fine chemistry 1
- Non-linear systems and methods for destination selectionUS 10,789,558 · granted SEP 29, 2020
- Methods for treating diabetes and reducing body weightUS 9,884,092 · granted FEB 6, 2018
- Engineered polypeptides having enhanced duration of actionUS 9,593,154 · granted MAR 14, 2017
- Hybrid polypeptides with selectable propertiesUS 9,453,063 · granted SEP 27, 2016
- Engineered polypeptides having enhanced duration of action with reduced immunogenicityUS 9,382,304 · granted JUL 5, 2016
Newest 5 shown · Granted to AstraZeneca Pharmaceuticals LP · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plants
2 FACILITIES| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | South San Francisco | CA | — | UNVERIFIED |
| Astrazeneca Pharmaceuticals | Coppell | TX | — | UNVERIFIED |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.